The AGE-receptor in the pathogenesis of diabetic complications

Diabetes/Metabolism Research and Reviews

Volumn 17, Issue 6, 2001, Pages 436-443

  Vlassara, Helen ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic vascular disease; Glycation; Nephropathy; Oxidation; Therapy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BINDING PROTEIN; CD36 ANTIGEN; GLUCOSE; SCAVENGER RECEPTOR;

ANIMAL CELL; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION FUNCTION; DIABETES MELLITUS; DIABETOGENESIS; DNA POLYMORPHISM; GENE EXPRESSION; GENE FUNCTION; GENETIC LINKAGE; GLIA CELL; HEMATOPOIETIC CELL; HUMAN; INFLAMMATION; KIDNEY CELL; KIDNEY PARENCHYMA; MOUSE; NERVE CELL; NERVOUS TISSUE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; VASCULAR TISSUE;

DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 0035668462     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.233     Document Type: Review

References (60)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
2. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking
3. Activation of receptor for advanced glycation end products; a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
4. Advanced glycation endproducts in patients with diabetic nephropathy
5. Reactive glycosylation endproducts in diabetic uremia and treatment of renal failure
6. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency
7. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor factor-alpha and interleukin-1
8. Advanced glycation products contribute to amyloidosis in Alzheimer's disease
9. Tobacco smoke is a source of toxic reactive glycation products
10. Orally absorbed reactive glycation products (glycotoxins): A potential risk factor in diabetic nephropathy
11. Dietary glycotoxin: Inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration
12. Two novel rat liver membrane proteins that bind advanced glycosylation end products: Relationship to macrophage receptor for glucose modified proteins
13. Molecular identity and cellular distribution of advanced glycation endproduct receptors: Relationship of p60 to OST-48 and p90 to 80K-H membrane proteins
14. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
15. Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: Relationship to tissue AGEs
16. Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kD protein
17. The 48-kDa subunit of the mammalian oligosaccharyltransferase complex is homologous to the essential yeast protein WBP1
18. Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products
19. Isolation of surface binding protein specific for advanced glycosylation end products from mouse macrophage-derived cell line raw 264.7
20. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors
21. Advanced glycosylation endproducts on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages; a model for turnover of aging cells
22. Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor stimulated cells, as 80K-H
23. Characterization of the advanced glycation endproduct receptor complex in human vascular endothelial cells
24. Identification of Galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE): A new member of the AGE-receptor complex
25. The human LGALS3 (Gelectin-3) gene: Determination of the gene structure and functional characterization of the promoter
26. The diabetic milieu modulates the AGE-receptor complex in the mesangium by inducing or upregulating galectin-3 expression
27. Advanced glycation endproduct receptor interactions on microvascular cells occur within caeolin-rich membrane domains
28. ε-(Carboxymethyl)-lysine adducts of proteins are ligands for RAGE that activate cell signaling pathways, and modulate gene expression
29. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE-proteins
30. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins
31. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction
32. Human blood-brain barrier receptors for Aβ 1-40
33. Cellular cofactors for amyloid β-peptide-induced cell stress; moving from cell culture to in vivo
34. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease
35. Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif
36. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products
37. CD36, a member of class B scavenger receptor family, as a receptor for advanced glycation end products (AGE)
38. Advanced glycation endproducts and their recognition by macrophage and macrophage-derived cells
39. Advanced glycation end products-induced gene expression of scavenger receptors in cultured human monocyte-derived macrophages
40. Pharmacological aspects and therapeutic applications of lysozymes
41. Depletion of reactive advanced glycation endproducts from diabetic uremic sera by a lysozyme-linked matrix
42. Lysozyme administration enhances renal excretion of advanced glycation endproducts in vivo and suppresses adverse AGE-mediated cellular effects in vitro
43. In vivo treatment of diabetic mice (NOD and db/db) with lysozyme (LZ) enhances renal clearance of glycoxidation products and prevents albuminuria
44. Inflammatory gene-activation and tissue cross-link formation are properties of dietary glycotoxins: Role of common foods in tissue injury and diabetic complications
45. Overexpression of human recombinant lysozyme (huLZ) by macrophages leads to enhanced glycotoxin uptake and clearance without cell activation; a new model approach for the prevention of diabetic complications
46. Lysozyme (LZ) is secreted by mesangial cells and inhibits glycoxidation-dependent glomerular gene dysregulation in vitro and in vivo: A novel defense mechanism against diabetic nephropathy
47. Glycated-LDL: A most powerful stimulus for endothelial cell p44/42 mitogen-activated protein kinase (MAPK) acts via AGE-receptor-2
48. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress
49. Specific macrophage receptor activity for advanced glycosylation end products inversely correlates with insulin levels in vivo
50. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor
51. Advanced non-enzymatic tissue glycosylation: Mechanism implicated in the complications associated with aging
52. Presence of diabetic complications in Type I diabetic patients correlates with low expression of mononuclear AGE-receptor-1 and elevated serum AGE
53. Advanced glycation endproducts (AGE) co-localize with receptors in the retinal vasculature of diabetic and of AGE-infused rats
54. Differential expression of renal AGE-receptor genes in NOD mice; possible role in NOD diabetic renal disease
55. Low expression of AGE-receptor-1 in NOD mouse mesangial cells: Possible link to diabetic nephropathy
56. Mononuclear (MN) cell AGE receptor-1 (AGE-R1) mRNA expression and its relationship to diabetic complications
57. Isolation of cDNAs encoding a substrate for protein kinase C: Nucleotide sequence and chromosomal mapping of the gene for a human 80K-H protein
58. Genome organization of human 48-kDa oligosaccharryltransferase (DDOST)
59. Polymorphism screening of four genes encoding advanced glycation end product putative receptors: Association study with nephropathy in Type 1 diabetes patients
60. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene